Patent
The present invention relates to polynucleotide sequences encoding novel Lawsonia intracellularis polypeptides. It also relates to DNA fragments, recombinant plasmid DNA and live recombinant microorganisms comprising these sequences. Moreover, the invention relates to polypeptides encoded by these nucleotide sequences. The invention also relates to immunogenic compositions for prevention of Lawsonia intracellularis infections and methods for the preparation of these immunogenic compositions. The invention also relates to diagnostic tests for the detection of Lawsonia intracellularis DNA, the detection of Lawsonia intracellularis antigens and detection of antibodies against Lawsonia intracellularis.
1. An immunogenic composition consisting of a first polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 5, 7, 9, 10; and 11; a second polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 12 and 13; and one or more pharmaceutically acceptable components selected from the group consisting of an appropriate pharmaceutical carrier and a pharmaceutically acceptable adjuvant.
2. The immunogenic composition of claim 1 wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, the combination of oil, water and aluminum hydroxide, Quil A, Quil A plus cholesterol, and Immune Stimulating Complex (ISCOM).
3. The immunogenic composition according to claim 1 wherein the first polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 9.
4. The immunogenic composition according to claim 3 wherein the second polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 13.
5. An immunogenic composition consisting of a first polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 5, 7, 9, 10, and 11; a second polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 12 and 13; one or more antigenic components of Mycoplasma hyopneumoniae Erysipelas spp. salmonella, Haemophilus parasuis, Clostridium spp. Streptococcus suis, Brachyspira spp. Bordetella, Pasteurella, Escherichia coli ( E. coli ), Coronavirus, Parvovirus, porcine reproductive and respiratory syndrome virus (PRRS), porcine circovirus (PCV), or swine influenza virus (SIV); and one or more pharmaceutically acceptable components selected from the group consisting of an appropriate pharmaceutical carrier and a pharmaceutically acceptable adjuvant.
6. The immunogenic composition of claim 5 wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, the combination of oil, water and aluminum hydroxide, Quil A, Quil A plus cholesterol, and Immune Stimulating Complex (ISCOM).
7. The immunogenic composition according to claim 6 wherein the first polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 9.
8. The immunogenic composition according to claim 7 wherein the second polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 13.
9. The immunogenic composition according to claim 5 wherein the first polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 9.
10. The immunogenic composition according to claim 9 wherein the second polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 13.
11. The immunogenic composition according to claim 2 wherein the first polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 9.
12. The immunogenic composition according to claim 11 wherein the second polypeptide has an amino acid sequence at least 90% identical to SEQ ID NO: 13.
13. An immunogenic composition consisting of one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 5, 7, 9, 10, and 11; one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 12 and 13; and one or more pharmaceutically acceptable components selected from the group consisting of an appropriate pharmaceutical carrier and a pharmaceutically acceptable adjuvant.
14. The immunogenic composition of claim 13 wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, the combination of oil, water and aluminum hydroxide, Quil A, Quil A plus cholesterol, and Immune Stimulating Complex (ISCOM).
15. An immunogenic composition consisting of one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 5, 7, 9, 10, and 11; one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 12 and 13; and one or more antigenic components of Mycoplasma hyopneumoniae Erysipelas spp, salmonella, Haemophilus parasuis, Clostridium spp. Streptococcus suis, Brachyspira spp. Bordetella, Pasteurella, Escherichia coli ( E. coli ), Coronavirus, Parvovirus, porcine reproductive and respiratory syndrome virus (PRRS), porcine circovirus (PCV), or swine influenza virus (SIV); and one or more pharmaceutically acceptable components selected from the group consisting of an appropriate pharmaceutical carrier and a pharmaceutically acceptable adjuvant.
16. The immunogenic composition of claim 15 wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, the combination of oil, water and aluminum hydroxide, Quil A, Quil A plus cholesterol, and Immune Stimulating Complex (ISCOM).